CoChat

NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

Open access
Pollack, Seth M., Jungbluth, Achim A., Hoch, Benjamin L., Farrar, Erik A., Bleakley, Marie, Schneider, David J., Loggers, Elizabeth T., Rodler, Eve, Eary, Janet F., Conrad, III, Ernest U., Jones, Robin L., Yee, Cassian · 2012 · Cancer
Cited by 125

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Myxoid/round cell liposarcoma (MRCL) is the second most common liposarcoma subtype, accounting for >33% of liposarcomas and approximately 10% of all soft tissue sarcomas. Although MRCL is a chemosensitive subtype, patients with metastatic disease have a poor outcome. NY‐ESO‐1 is a cancer‐testis antigen (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T‐cell therapy trials for the treatment of several solid tumors. METHODS: The authors investigated the feasibility of targeting NY‐ESO‐1 in patients with MRCL by evaluating the prevalence of NY‐ESO‐1 expression in tumors using immunohistochemistry and quantitative reverse transcriptase‐polymerase chain reaction analysis. NY‐ESO‐1–specific tumor recognition by NY‐ESO‐1–specific T‐cells also was analyzed using a chromium release assay. RESULTS: A search of the University of Washington Sarcoma Tissue Bank identified paraffin‐embedded tumor samples from 25 patients with MRCL. NY‐ESO‐1 expression was observed in every MRCL tumor assessed (100%); in 18 tumors (72%), staining was homogenous. In all but 2 tumors, staining was sufficiently robust (2+) that such patients would be eligible for clinical trials of NY‐ESO‐1–directed therapy. By using NY‐ESO‐1 specific, CD8‐positive T‐cells, the in vitro sensitivity of myxoid liposarcoma cell lines to antigen‐specific lysis was demonstrated. CONCLUSIONS: The current results establish NY‐ESO‐1 as an important target antigen for the treatment of patients with MRCL. Cancer 2012. © 2012 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.27446

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 125

Metadata

Authors
Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E., Eary, J. F., Conrad, III, Jones, R. L., & Yee, C.
Venue
Cancer
Publisher
Wiley
Published
2012-02-22
Volume
118
Issue
18
Pages
4564-4570
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1572718168
Cited by
125
References
2
FWCI
6.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. https://app.cochat.ai/papers/10.1002/cncr.27446
The paper
Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E., Eary, J. F., Conrad, III, Jones, R. L., & Yee, C. (2012). NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. https://doi.org/10.1002/cncr.27446

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.